BioMarin Pharmaceutical Stock Price

-0.18 (-0.15%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
BioMarin Pharmaceutical Inc BMRN NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
-0.18 -0.15% 119.65 118.36 120.66 119.60 119.83 17:15:00
Bid Price Ask Price Spread Spread % News
119.00 121.20 2.20 1.82% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
11,813 642,581 $ 119.29 $ 76,656,231 1,378,387 62.88 - 131.945
Last Trade Time Type Quantity Stock Price Currency
16:09:23 40 $ 119.65 USD

BioMarin Pharmaceutical Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 21.64B 180.84M 158.02M $ 1.70B $ 181.99M -0.14 196.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

BioMarin Pharmaceutical News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BMRN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week119.21124.5199117.72120.581,042,0030.440.37%
1 Month129.00131.945117.72124.571,043,335-9.35-7.25%
3 Months93.86131.94589.20114.841,404,26625.7927.48%
6 Months89.89131.94568.2598.741,531,47929.7633.11%
1 Year76.69131.94562.8888.721,430,04142.9656.02%
3 Years89.82131.94562.8889.201,279,16329.8333.21%
5 Years143.57143.919962.1290.411,310,381-23.92-16.66%

BioMarin Pharmaceutical Description

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.